Dalia Saleh | Cancer Cell Biology | Innovative Research Award

Posted on by sciencefather

Prof . Dalia Saleh | Cancer Cell Biology | Innovative Research Award

Prof . Dalia Saleh | National Research Centre | Egypt

Dr. Dalia Osama Abd El Fattah Saleh is a distinguished pharmacologist with over two decades of experience in experimental pharmacology and drug development. She holds a Ph.D. in Pharmacology from Cairo University and currently serves as a Professor at the National Research Centre in Cairo, Egypt. Dr. Saleh has contributed to numerous high-impact scientific journals and has led pioneering work in the areas of metabolic disorders, drug safety, and vascular pharmacology. Her multidisciplinary collaborations and continuous professional development from institutions like King’s College London demonstrate her dedication to excellence in research and education. She is also recognized for her commitment to academic instruction and quality assurance, having served as a Quality Assurance Director. Her work bridges scientific discovery and real-world therapeutic applications, making her a strong candidate for innovation-focused research awards.

publication profile:

scopus

Strengths for the Award:

  1. Robust Academic Background:
    Dr. Saleh holds a Ph.D. in Pharmacology from Cairo University and has a long-standing academic and research career in pharmacology and drug development. Her doctoral and master’s theses reflect a strong foundation in vascular pharmacology, metabolic disorders, and endocrine influence—fields of enduring relevance.

  2. Consistent Research Productivity:
    Her recent publication record (2022–2024) is prolific and impactful, with studies published in high-visibility journals such as Scientific Reports, Biochemistry and Cell Biology, Naunyn-Schmiedeberg’s Archives of Pharmacology, and Environmental Science and Pollution Research. Her work covers cutting-edge pharmacological topics, including:

    • AMPK/mTOR signaling pathways,

    • Neuroprotection and anti-inflammatory mechanisms,

    • Herbal and synthetic compounds in disease modulation,

    • Hepatic encephalopathy, diabetic nephropathy, and cystitis models.

  3. Interdisciplinary and Translational Approach:
    Dr. Saleh bridges basic pharmacological research with clinical relevance. Her investigations into molecular pathways (e.g., NF-κB, PI3K/Akt, SIRT-1) are grounded in disease models, thus demonstrating translational potential. Her inclusion of both natural and synthetic agents further adds diversity and innovation to her research.

  4. Capacity Building and International Exposure:
    She has participated in Continuing Professional Development modules at King’s College London, emphasizing drug safety, statistics, and ethics—key areas in modern drug development. This international engagement underscores her commitment to staying updated and aligned with global standards.

  5. Institutional Contribution and Leadership:
    As a Professor and former Quality Assurance Director at the National Research Centre (NRC), she has contributed to institutional excellence, including achieving ISO 9001/2008 certification. These roles reflect her leadership, organizational, and strategic planning skills.

Areas for Improvement:

  1. Principal Investigator Leadership:
    While her name appears consistently in multi-author studies, further highlighting her role as the principal investigator (PI) or corresponding author could strengthen her case for innovation leadership.

  2. Patents or Product Development:
    There is no mention of patents or direct product development based on her findings. Translating research into tangible therapeutics or clinical trials would significantly elevate her eligibility for innovation-specific awards.

  3. Global Collaborations and Grants:
    Although she has participated in international seminars, active global collaborations or leading major international grants/projects would further establish her as a global innovator.

  4. Public/Industry Impact:
    While the academic impact is strong, showcasing industry partnerships or policy-level influence (e.g., contributions to clinical guidelines or regulatory science) would align more directly with innovation awards that emphasize practical application.

🎓 Education Summary :

Dr. Dalia Saleh completed her higher education at Cairo University’s Faculty of Pharmacy, where she earned her Master of Science in Pharmacology in 2009 and Doctor of Philosophy in Pharmacology in 2012. Her M.Sc. thesis focused on the vascular and biochemical effects of rosiglitazone in diabetic rats, reflecting early interests in metabolic pharmacology. Her Ph.D. expanded on this foundation by exploring estrogen’s potential role in managing vascular changes related to insulin resistance. Both theses demonstrated robust experimental designs and contributed new insights into the interplay between hormonal and metabolic pathways in disease models. Dr. Saleh has since built on this academic background with advanced training in clinical drug development, safety, and biostatistics at King’s College London in 2023, indicating a continued commitment to integrating modern pharmaceutical science and translational research into her academic portfolio. This rich educational foundation underpins her success as a researcher and educator.

🔬 Research Focus :

Dr. Saleh’s research focuses on experimental pharmacology, with a special interest in metabolic diseases, drug-induced toxicities, inflammation, and vascular pharmacology. Her studies frequently involve animal models to investigate the mechanisms of drug action and to evaluate the protective or therapeutic roles of natural products and synthetic compounds. A recurring theme in her work is exploring the modulation of signaling pathways like AMPK, NF-κB, PI3K/mTOR, and Nrf2 in the context of oxidative stress, inflammation, and cellular apoptosis. She has also studied the role of hormonal influences in disease models, such as estrogen’s effect on insulin resistance. Her research employs modern analytical techniques and integrates molecular biology with pharmacodynamics to derive mechanistic insights. This strong focus on mechanistic pharmacology enhances her work’s relevance in drug development, particularly for conditions such as diabetic complications, hepatic encephalopathy, nephropathy, and chemotherapy-induced toxicities.

📚 Publications Top Note:

  1. 🧪 Eugenol alleviates acrylamide-induced testicular toxicity via AMPK/pAKT/mTOR modulation – Scientific Reports, 2024

  2. 🧠 Trimetazidine prevents cisplatin neuropathy through AMPK, Nrf2, and NF-κB pathways – Biochemistry and Cell Biology, 2023

  3. 🔬 Novel chromone-thiazolopyrimidines as TNF-α, IL-6, and PGE2 inhibitors – Polycyclic Aromatic Compounds, 2023

  4. 🚽 Chrysin protects against cyclophosphamide-induced hemorrhagic cystitis via anti-inflammatory signaling – Chemico-Biological Interactions, 2023

  5. 🧃 Linagliptin & L-arginine synergy in gastric hyperacidity via EP4 receptor upregulation – Naunyn-Schmiedeberg’s Archives of Pharmacology, 2023

  6. 🧠 L-arginine reduces thioacetamide-induced hepatic encephalopathy via NF-κB downregulation – Environmental Science and Pollution Research, 2023

  7. 🌿 Calotropis procera seed oil shows anti-inflammatory and antiparasitic activity – Arabian Journal of Chemistry, 2022

  8. 🛡️ Olmesartan mitigates diabetic nephropathy via AGE/PKC and TLR4/SIRT-1 pathways – European Journal of Pharmacology, 2022

  9. 🍃 Plumbago species show anti-fibrotic effects in liver fibrosis rat models – Scientific Reports, 2022

  10. 🫀 Omega-3 combats doxorubicin-induced liver toxicity via Nrf2/PI3K/Akt signaling – Pending Publication

Conclusion:

Dr. Dalia O. Saleh presents a strong candidacy for the Research for Innovative Research Award, particularly due to her sustained publication record, mechanistic depth in pharmacology, and commitment to professional development and institutional excellence. Her work spans innovative mechanistic explorations and novel therapeutic evaluations, showing real promise in addressing current pharmacological challenges.

Yan Jiao | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Dr. Yan Jiao | Cancer Cell Biology | Best Researcher Award

Dr. Yan Jiao, First Hospital of Jilin University, China

Dr. Yan Jiao is an accomplished Attending Physician and clinical researcher at the First Hospital of Jilin University, specializing in hepatobiliary and pancreatic diseases. With dual degrees—a Bachelor of Medicine and a Ph.D. from Jilin University—Dr. Jiao has combined clinical acumen with deep expertise in bioinformatics and statistical analysis. A prolific researcher, Dr. Jiao has published extensively on topics ranging from liver cancer and immunotherapy to the adverse effects of diagnostic dyes and post-surgical complications. Notably, Dr. Jiao has contributed to scientific integrity through independent verification of published data and has reported anomalies that led to editorial actions. Skilled in R programming and mining public health datasets, Dr. Jiao blends analytical precision with a commitment to improving patient outcomes. Recognized for a meticulous approach to research, Dr. Jiao’s work exemplifies scientific rigor and ethical responsibility, making a compelling case for the Best Researcher Award.

Publication Profile:

Orcid

✅ Strengths for the Award:

  1. Outstanding Publication Record:
    Dr. Jiao has co-authored over 20 peer-reviewed journal articles in high-impact journals like Scientific Reports, International Journal of Nanomedicine, and World Journal of Gastrointestinal Surgery. The research spans critical fields like liver cancer, gastric cancer, bioinformatics, and surgical safety, demonstrating multidisciplinary excellence.

  2. High Ethical Standards:
    A rare and commendable contribution is Dr. Jiao’s work in scientific integrity—verifying published studies, detecting image manipulation, and triggering investigations into misconduct. This highlights not only academic rigor but also moral responsibility in research.

  3. Bioinformatics Expertise:
    Proficient in R programming and analysis of large public datasets (FAERS, NHANES, TCGA), Dr. Jiao merges clinical insight with data science to generate real-world impact. The capacity to handle complex data with statistical precision is vital in modern medical research.

  4. Clinical & Research Integration:
    As a practicing Attending Physician in hepatobiliary and pancreatic diseases, Dr. Jiao directly applies research outcomes to clinical settings. This dual competency strengthens translational research and improves patient-centered outcomes.

  5. Collaborative Network:
    Dr. Jiao has worked with a wide range of co-authors, showing adaptability and a collaborative spirit. This not only strengthens individual studies but also reflects influence within a broader research community.

🛠️ Areas for Improvement:

  1. Global Research Visibility:
    While Dr. Jiao has a strong publication portfolio, more engagement with global conferences, keynote presentations, and international collaborations would enhance international recognition.

  2. Grant Leadership:
    There is limited information on independent research funding or grant leadership. Applying for and leading funded projects could further establish Dr. Jiao’s credentials as a principal investigator.

  3. First-Author Publications:
    Though a frequent contributor, a higher proportion of first-author or corresponding-author roles would solidify recognition as a lead researcher, particularly in high-impact original studies.

🎓 Education:

Dr. Yan Jiao pursued both undergraduate and doctoral studies at Jilin University, one of China’s top research institutions. From 2011 to 2016, Dr. Jiao earned a Bachelor of Medicine, laying the groundwork in clinical sciences and human biology. Continuing seamlessly into advanced research, Dr. Jiao completed a Ph.D. at the same university from 2016 to 2019, with a focus on hepatobiliary diseases and translational bioinformatics. The doctoral training combined clinical exposure with robust coursework in molecular biology, epidemiology, and data science. This dual qualification reflects a rare integration of frontline medical experience and deep academic inquiry, preparing Dr. Jiao for a career at the intersection of medicine, research, and technological innovation. Throughout academic training, Dr. Jiao demonstrated a strong aptitude for evidence-based medicine and statistical modeling, gaining recognition for a disciplined and inquisitive approach. The education path reflects a trajectory of consistent excellence and interdisciplinary competence.

💼 Professional Experience:

Dr. Yan Jiao currently serves as an Attending Physician at the First Hospital of Jilin University, where the clinical focus lies in hepatobiliary and pancreatic diseases. In this role, Dr. Jiao combines patient care with research initiatives, particularly in liver cancer. Beyond clinical duties, Dr. Jiao is actively engaged in bioinformatics research, utilizing datasets like FAERS, TCGA, and NHANES to uncover patterns in disease and treatment outcomes. With expert-level proficiency in R programming, Dr. Jiao conducts complex statistical analyses and visualizations. A distinct part of Dr. Jiao’s experience involves auditing the scientific literature for data anomalies and image manipulation, contributing anonymously to investigations into research misconduct. This dual role as a clinician and data scientist uniquely positions Dr. Jiao to address both practical and theoretical challenges in healthcare. Dr. Jiao’s professional journey underscores a rare blend of technical skills, ethical vigilance, and medical expertise, reinforcing eligibility for prestigious research awards.

🔬 Research Focus:

Dr. Yan Jiao’s research is deeply rooted in hepatobiliary oncology, with a specific focus on liver cancer diagnosis, treatment strategies, and prognosis modeling. Integrating clinical insights with computational analysis, Dr. Jiao utilizes large public datasets like TCGA, FAERS, and NHANES to examine treatment efficacy, drug safety, and genetic risk factors. A significant thrust of the research lies in immunotherapy, chemoembolization techniques, and the safety of diagnostic agents like Indocyanine Green. Dr. Jiao also explores post-operative complications and gastrointestinal disorders, broadening the scope of clinical relevance. Equally important is the investigation into scientific integrity, where Dr. Jiao’s efforts in identifying manipulated data and statistical inconsistencies have led to editorial scrutiny in major journals. By bridging bioinformatics with hands-on medical practice, the research offers both theoretical advancements and actionable clinical solutions. Dr. Jiao’s focus is future-facing, centered on personalized treatment and real-world data analysis to optimize patient outcomes.

📚 Publications Top Notes:

  1. 📉 Obesity-Surgery is not the end.

  2. 💉 Landscape of transarterial chemoembolization for hepatocellular carcinoma.

  3. 🧬 Immunotherapy for metastatic gastric cancer.

  4. ⚠️ Exploring the dark side of diagnostic dyes – Indocyanine green.

  5. 🧬 Long non-coding RNA HOTAIR in liver cancer cell behavior.

  6. 🧪 Abraxane-related adverse events – FAERS decade-long analysis.

  7. 🧬 Personalized treatment of perihilar cholangiocarcinoma.

  8. 💊 Impact of immunotherapy on liver metastasis.

  9. 🏥 Incisional hernia after laparoscopic colorectal surgery.

  10. 🔍 Intestinal Behçet’s disease: Diagnosis and treatment.

🧾 Conclusion:

Dr. Yan Jiao is a highly qualified and deserving candidate for the Best Researcher Award. With an exceptional combination of clinical experience, research productivity, ethical vigilance, and bioinformatics expertise, Dr. Jiao stands out as a well-rounded and impactful medical scientist. While there is room to further elevate global visibility and leadership in grant-funded research, the current portfolio already reflects excellence in translational science and data-driven healthcare. In conclusion, Dr. Jiao’s contributions are not only prolific but principled—making this nomination both timely and justified.

Dalia Saleh | Cancer Cell Biology | Innovative Research Award

Posted on by sciencefather

Prof. Dalia Saleh | Cancer Cell Biology | Innovative Research Award

Prof. Dalia Saleh, National Research Centre, Egypt

Dr. Dalia Osama Abd El Fattah Saleh is a distinguished pharmacologist and professor at the National Research Centre, Cairo, Egypt. With a career spanning over two decades in academic and pharmaceutical research, she specializes in molecular pharmacology, experimental therapeutics, and drug development. She earned her Ph.D. and M.Sc. in Pharmacology from Cairo University, where she also completed her undergraduate pharmacy degree with honors. Dr. Saleh’s prolific contributions to science are reflected in her extensive publication record, focusing on novel therapeutic strategies against various toxicological, metabolic, and inflammatory disorders. Her collaborative efforts have led to advancements in drug signaling pathways, phytochemical pharmacology, and nanotechnology-based delivery systems. Recognized nationally for her innovation, she has received several prestigious awards. Dr. Saleh continues to shape pharmacological research through her dedication to translational science, mentorship, and participation in international seminars and training programs.

Publication Profile: 

Google Scholar

✅ Strengths for the Award:

  • Extensive Academic Background: Holds a Ph.D., M.Sc., and B.Sc. in Pharmacology from Cairo University, with a clear focus on endocrine and vascular pharmacology from early in her career.

  • Distinguished Research Record: Authored over 25+ high-impact publications in peer-reviewed journals including Scientific Reports, Toxicology Reports, Biochemistry and Cell Biology, and Environmental Science and Pollution Research.

  • Novel Scientific Contributions:

    • Explores molecular pharmacology through cutting-edge therapeutic approaches like AMPK/mTOR signaling, Nrf2/NF-κB modulation, and natural compound pharmacodynamics.

    • Studies involve both synthetic and phytochemical-based interventions, representing a hybrid and innovative research style.

  • Awards and Recognition:

    • National recognition for her research quality and productivity by the National Research Centre, with awards received in 2015 and 2020.

    • Ranked 24th in the institution for publication volume in 2014—an indicator of sustained output.

  • Global Exposure: Participated in professional training programs at King’s College London, enhancing her knowledge in clinical drug development and data management—an asset for interdisciplinary and translational research.

  • Leadership and Longevity: Promoted through all academic ranks at NRC, from Research Assistant to Professor, demonstrating not only competence but leadership and mentorship over time.

Areas for Improvement:

  • Clinical Translation: While the preclinical research is extensive, initiating clinical trials or translational studies would further strengthen the real-world applicability of her findings.

  • Global Visibility: Although trained internationally, more international speaking engagements, keynote invitations, or editorial roles could enhance global recognition.

  • Interdisciplinary Projects: Expanding collaborations across fields such as bioinformatics or biotechnology could amplify the innovation aspect of her work.

🎓 Education:

Dr. Dalia Saleh obtained all her academic degrees from Cairo University’s esteemed Faculty of Pharmacy. She was awarded her Ph.D. in Pharmacology in 2012 for her thesis examining estrogen’s vascular effects in insulin-resistant, ovariectomized rats. Earlier, she earned her M.Sc. in 2009 with research on rosiglitazone’s effects in streptozotocin-induced vascular changes. Her academic journey began with a B.Sc. in Pharmacy in 2002, graduating with distinction and honors. Her strong educational foundation laid the groundwork for her innovative and interdisciplinary research spanning molecular pharmacology, toxicology, and metabolic disorders. Through continuous professional development, including modules at King’s College London, Dr. Saleh stays aligned with global standards in pharmacological science and clinical drug development. Her educational background combines academic excellence with practical research expertise, making her well-equipped to address complex biomedical challenges.

👩‍🔬 Experience:

Dr. Dalia Saleh has built a progressive research career at Egypt’s National Research Centre, beginning as a Research Assistant in 2003. Over the years, she rose through the ranks to become a Professor in 2022. She previously held positions as Researcher (2012–2017) and Assistant Professor (2017–2022). Throughout her tenure, she has actively contributed to preclinical pharmacology research, focusing on inflammation, neuroprotection, metabolic diseases, and organ toxicity. Her interdisciplinary approach integrates pharmacodynamics, molecular signaling, and therapeutic intervention studies using both synthetic and natural compounds. She has led numerous studies that explore drug mechanisms at cellular and systemic levels, often employing rodent disease models. Dr. Saleh’s active participation in international training (e.g., at King’s College London) highlights her global engagement and commitment to continuous learning. Her career reflects not only research productivity but also leadership in collaborative scientific initiatives and mentoring of emerging researchers.

🏆 Awards & Honors:

Dr. Dalia Saleh has received multiple accolades that underscore her impact in the field of pharmacology. She was honored with the 2020 Scientific Pioneers Award and the 2015 Scientific Encouragement Award from Egypt’s National Research Centre (NRC), recognizing her outstanding research contributions. In 2014, she received institutional recognition for both her high publication output (ranked 24th NRC-wide) and for publishing in a high-impact journal (impact factor 4.067). These achievements highlight her consistent scientific productivity and influence in biomedical research. Dr. Saleh’s awards reflect a career driven by innovation, rigor, and dedication to solving pressing health issues. Her work continues to be widely cited and applied in translational pharmacology, securing her reputation as a leading figure in her discipline. She remains an inspiration to peers and students alike, with a legacy of both scientific excellence and mentorship.

🔬 Research Focus:

Dr. Dalia Saleh’s research is rooted in experimental pharmacology, with an emphasis on cell signaling pathways, drug discovery, and natural compound pharmacodynamics. She investigates molecular mechanisms underlying chronic diseases such as diabetes, hepatic and renal injury, neurodegeneration, and inflammatory disorders. A recurring theme in her work is the modulation of key signaling axes (e.g., AMPK/mTOR, NF-κB, PI3K/Akt) in mitigating organ toxicity and disease progression. Her recent studies explore the pharmacological potential of phytochemicals, drug hybrids, and nanoformulations in preclinical models. Dr. Saleh also examines gender-specific pathophysiology, as seen in her Ph.D. research on estrogen’s role in vascular dysfunction. She actively integrates biochemical, histological, and behavioral endpoints to ensure translational relevance. By bridging traditional medicine and molecular pharmacology, her work contributes to next-generation therapeutics and precision medicine. Her research has both national and global impact, frequently published in high-tier journals and cited in clinical research discussions.

📚 Publications Top Notes:

  1. 🧬 Eugenol alleviates acrylamide-induced testicular toxicity via AMPK/pAKT/mTOR signaling – Scientific Reports, 2024

  2. 💊 Trimetazidine protects against cisplatin-induced neuropathy via AMPK and Nrf2 pathways – Biochemistry and Cell Biology, 2023

  3. 🧪 Chromone-thiazolopyrimidine hybrids inhibit TNF-α, IL-6, and PGE2 – Polycyclic Aromatic Compounds, 2023

  4. 🧻 Chrysin counters cyclophosphamide-induced cystitis via STAT-3 and NF-κB inhibition – Chemico-Biological Interactions, 2023

  5. 🩺 Linagliptin and L-arginine synergize in hyperacidity via EP4 upregulation – Naunyn-Schmiedeberg’s Archives of Pharmacology, 2023

  6. 🧠 L-arginine protects against hepatic encephalopathy via anti-apoptotic mechanisms – Environmental Science and Pollution Research, 2023

  7. 🌿 Calotropis procera seed oil shows anti-inflammatory and antiparasitic activity – Arabian Journal of Chemistry, 2022

  8. 🧫 Olmesartan mitigates diabetic nephropathy through TLR4/P38-MAPK modulation – European Journal of Pharmacology, 2022

  9. 🌱 Anti-fibrotic activities of Plumbago species in liver fibrosis models – Scientific Reports, 2022

  10. 🐟 Omega-3 fatty acids protect against doxorubicin-induced liver damage – Saudi Journal of Biological Sciences, 2022

Conclusion:

Dr. Dalia O. Saleh is highly suitable for the Best Researcher Award based on her prolific scientific contributions, consistent academic progression, and commitment to impactful pharmacological research. Her strength lies in combining rigorous mechanistic studies with applied therapeutic exploration, especially in inflammation, oxidative stress, and natural product pharmacology.

wenhao chen | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Prof. wenhao chen | Cancer Cell Biology | Best Researcher Award

Prof. wenhao chen , Zhejiang University School of Medicine Children’s Hospital National Clinical Research Center for Child Health , China

Dr. Wenhao Chen, a leading orthopedic surgeon and researcher, currently serves as the Head of the Department of Orthopedics at the Children’s Hospital, Zhejiang University School of Medicine. At 38, he has made substantial contributions to pediatric orthopedics, bone oncology, and regenerative medicine. Dr. Chen obtained his MD from Peking University and completed a prestigious postdoctoral fellowship at Massachusetts General Hospital. Known for integrating clinical expertise with biomedical research, he has authored over 17 high-impact papers, applying advanced techniques such as machine learning, gene profiling, and CRISPR screening in orthopedic studies. His work spans rare skeletal diseases, cancer metastasis, and spinal cord repair. Recognized internationally, he continues to mentor young researchers and lead translational projects. With a vision toward improving musculoskeletal health in children, his multidisciplinary approach positions him as a strong contender for the Best Researcher Award.

Publication Profile:

Orcid

✅ Strengths for the Award:

  1. Outstanding Research Productivity:
    Dr. Chen has authored over 18 high-impact, peer-reviewed publications in prestigious journals such as FASEB Journal, QJM, Journal of Translational Medicine, and Journal of Orthopaedic Research. His work spans orthopedics, oncology, regenerative medicine, and computational biology.

  2. Interdisciplinary Expertise:
    He integrates molecular biology, AI, proteomics, CRISPR screening, and clinical research, particularly in osteosarcoma, Ewing sarcoma, spinal cord repair, and rare pediatric skeletal diseases.

  3. Clinical and Academic Leadership:
    As Head of the Department of Orthopedics at a leading children’s hospital and faculty member at Zhejiang University, he demonstrates clinical leadership and research excellence.

  4. International Experience:
    His postdoctoral fellowship at Massachusetts General Hospital, USA, reflects global research exposure and cross-cultural collaboration.

  5. Translational Impact:
    Dr. Chen’s research shows a clear clinical application, such as prognosis prediction models, radiotherapy effectiveness evaluation, and gene therapy strategies for rare disorders and cancer.

🔧 Areas for Improvement:

  1. Visibility in Global Academic Forums:
    While his research is impactful, increased participation in international conferences, workshops, and symposiums could enhance visibility and networking.

  2. First-/Last-Author Publications:
    While present, a greater proportion of senior authorship could strengthen his recognition as a principal investigator or thought leader in major studies.

  3. Grant Leadership & Patent Output:
    There’s limited publicly shared information on research grants led or intellectual property (e.g., patents), which could further validate his innovation and translational output.

🎓 Education:

Dr. Wenhao Chen began his medical journey in 2004 at Peking University, one of China’s most prestigious institutions, where he completed his MD program over eight years (2004–2012). This comprehensive training gave him a robust foundation in clinical medicine and surgical practice. As part of his pursuit of global excellence, Dr. Chen was selected for a postdoctoral research position at Massachusetts General Hospital (2019–2020), affiliated with Harvard Medical School. During this international fellowship, he engaged in advanced research in orthopedics, including joint reconstruction, stem cell applications, and musculoskeletal oncology. His education reflects not only academic brilliance but also an openness to cross-border scientific collaboration. Dr. Chen’s diverse educational background enables him to merge Eastern clinical insights with Western research innovations, which he continues to apply in developing pediatric orthopedic interventions and understanding skeletal disorders on a molecular level.

💼 Experience:

With over a decade of experience in clinical orthopedics and research, Dr. Wenhao Chen leads the Department of Orthopedics at the Children’s Hospital of Zhejiang University School of Medicine. His career began in top-tier clinical hospitals in China and expanded to the U.S. during his postdoctoral fellowship at Massachusetts General Hospital, where he worked on joint reconstruction and bone oncology. In his current leadership role, he spearheads surgical treatment strategies, oversees translational research projects, and mentors medical trainees. Dr. Chen’s experience spans pediatric orthopedic deformities, osteosarcoma, Ewing sarcoma, and regenerative therapies. He’s an expert in the application of genomics, CRISPR screens, and AI in musculoskeletal disorders. His multidisciplinary projects have led to multiple grants and collaborations. Dr. Chen’s leadership extends beyond the hospital into academia, where he regularly publishes in peer-reviewed journals and reviews manuscripts. His balance of surgical excellence and innovation defines his professional experience.

🔬 Research Focus:

Dr. Wenhao Chen’s research centers on pediatric orthopedics, bone tumors (especially osteosarcoma and Ewing sarcoma), regenerative medicine, and translational oncology. He focuses on unraveling the molecular mechanisms of musculoskeletal disorders through multi-omics profiling, CRISPR screening, and machine learning. A significant part of his work addresses prognostic modeling using genomic and metabolic markers. He has also pioneered studies on gene therapy using viral vectors for spinal cord repair and the application of stem cells in congenital skeletal diseases like mucopolysaccharidosis IVA. Additionally, he investigates inflammation and autophagy signaling pathways, notably the PI3K/AKT/GSK3β axis in bone homeostasis. His translational research aims to convert biological findings into targeted clinical therapies. Dr. Chen’s work is consistently published in top-tier journals and has influenced diagnostic and therapeutic protocols in orthopedics. His blend of computational biology, clinical acumen, and lab innovation defines his impactful and forward-looking research portfolio.

📚 Publications Top Notes:

  1. 🧬 Diminished GALNS activity in iPSCs of MPS IVA caused by compound mutations – QJM, 2024

  2. 🧪 LARS as essential gene for osteosarcoma proliferation via CRISPR screening – J Transl Med, 2022

  3. 🌬️ Itraconazole mitigates lung fibrosis via SPP1/C3 signaling – J Transl Med, 2024

  4. 🔬 Chaperone-mediated autophagy protects bone formation via PI3K/AKT pathway – FASEB J, 2024

  5. 🧠 Predicting metastasis and radiotherapy effectiveness in metastatic osteosarcoma – J Cancer Res Clin Oncol, 2023

  6. 🤖 Machine learning predicts prognosis in Ewing sarcoma patients – J Orthop Res, 2021

  7. ⚡ Glycolysis-related gene score predicts osteosarcoma survival – J Orthop Res, 2022

  8. 🧫 Candidate proteins for astrocyte-to-neuron conversion via proteomics – Neural Regen Res, 2021

  9. 🦴 Surgery ± radiotherapy for malignant giant cell tumor of bone/soft tissue – J Orthop Res, 2020

  10. 🧠 NeuroD1 gene promotes glial-to-neuron conversion post-spinal cord injury – Brain Res Bull, 2017

🧾 Conclusion:

Dr. Wenhao Chen is a highly accomplished orthopedic surgeon-scientist whose interdisciplinary research portfolio, leadership in pediatric musculoskeletal science, and international collaborations make him an exceptional candidate for the Best Researcher Award. His extensive body of work, blending molecular biology with clinical application, showcases both depth and innovation, especially in addressing complex skeletal disorders and musculoskeletal oncology. With a few enhancements in international visibility and grant leadership, he is well on the path to becoming a global leader in orthopedic research.

Sen Wang | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Ms. Sen Wang | Cancer Cell Biology | Best Researcher Award

Ms. Sen Wang , Affiliated Hospital of Jining Medical College , China

Dr. Wang Sen is an accomplished researcher and Deputy Chief Technician at the Affiliated Hospital of Jining Medical University. With a Ph.D. in Pharmaceutical Engineering and a postdoctoral fellowship at Shandong University of Traditional Chinese Medicine, he has developed deep expertise in molecular oncology, tumor microenvironments, and translational medicine. His career spans over a decade, marked by significant research in gastrointestinal and renal cancers, exploring mechanisms of autophagy, endothelial dysfunction, and tumor angiogenesis. Dr. Wang has led and contributed to several prestigious research projects, including National Natural Science Foundation grants. He has published in high-impact journals and holds patents that support translational applications in oncology. Recognized by peers and institutions alike, he received the Shandong Medical Association Youth Science and Technology Award. His work continues to push boundaries in cancer research, demonstrating strong scientific leadership and a commitment to improving therapeutic strategies.

Publication Profile: 

Scopus

✅ Strengths for the Award

  1. Extensive Research Background
    Dr. Wang has demonstrated a consistent and deep involvement in cutting-edge cancer research, especially focusing on tumor microenvironment regulation, autophagy, and angiogenesis—key areas in translational oncology.

  2. Prolific Publication Record
    He is the sole first author of several papers published in high-impact journals like British Journal of Cancer, Cell Death & Disease, and Scientific Reports. These contributions indicate scientific independence and strong writing and experimental skills.

  3. Leadership in Funded Projects
    He has served as Principal Investigator (PI) on multiple prestigious projects, including the NSFC Youth Fund and China Postdoctoral Foundation grants, which testifies to his research leadership and capability in securing competitive funding.

  4. Innovative Impact through Patents
    Dr. Wang is a co-inventor of three Chinese patents, including a novel therapeutic application of MT1G in renal cancer—highlighting a strong translational component in his research.

  5. Academic Awards and Recognition
    His receipt of the Shandong Medical Association Youth Science and Technology Award (Second Prize) in 2024 is an external validation of his scientific excellence at the provincial level.

  6. Collaborative and Interdisciplinary Approach
    His co-authorship with experts across molecular biology, pharmacology, and clinical research demonstrates a collaborative nature crucial for multidisciplinary medical advancements.

📈 Areas for Improvement

  1. International Recognition
    While Dr. Wang’s work is commendable within China, increasing collaboration or recognition on an international level (e.g., international conferences, global research networks) would further elevate his research visibility.

  2. Citations and Real-world Applications
    Some of his recent papers have not yet garnered citations. Continued dissemination, follow-up studies, and clinical application testing will help boost impact.

  3. Expanded Mentorship Role
    There is limited information on his mentorship of young scientists or PhD students. Strengthening academic mentorship could broaden his influence within the scientific community.

🎓 Education:

Dr. Wang Sen has pursued a comprehensive academic path in life sciences and medical research. He earned his Ph.D. in Pharmaceutical Engineering from Chongqing Medical University (2016–2019), following a Master’s degree in Biochemistry and Molecular Biology at the same institution (2013–2016). His foundational training began with a Bachelor’s degree in Biological Engineering from Jining University (2009–2013), where he laid the groundwork for his interest in molecular biology and drug development. His doctoral and master’s work focused on cancer biology, signaling pathways, and translational medicine—preparing him for cutting-edge postdoctoral research at Shandong University of Traditional Chinese Medicine (2022–2024). This academic journey has equipped him with strong theoretical and experimental skills that he applies in both clinical and laboratory settings.

🧪 Experience:

Dr. Wang Sen currently serves as Deputy Chief Technician at the Affiliated Hospital of Jining Medical University (since Nov 2024). Prior to this, he held the role of Chief Technician (2019–2024) at the same hospital, where he led several translational cancer research projects. His responsibilities include designing experimental protocols, overseeing clinical collaboration, and mentoring junior researchers. His postdoctoral research (2022–2024) at Shandong University of Traditional Chinese Medicine focused on tumor angiogenesis and metabolic regulation. Throughout his academic and professional journey, he has shown a keen interest in understanding cancer cell signaling, tumor-endothelial interactions, and the development of therapeutic targets. His multidisciplinary expertise makes him a vital contributor to collaborative projects in molecular medicine and drug discovery.

🏆 Awards and Honors:

Dr. Wang Sen’s contributions to medical research have earned him notable recognition. In 2024, he received the Shandong Medical Association Youth Science and Technology Award (Second Prize), celebrating his innovative work in cancer biology. He is also a co-inventor on three Chinese patents, including the application of MT1G protein inhibitors for renal cancer and methods related to small molecule metabolite ligands and exosome preparation. These patents demonstrate his commitment to translational research and innovation in therapeutic development. Additionally, his participation in collaborative high-impact publications and national grants has solidified his reputation as a rising leader in biomedical sciences. His academic integrity, technical depth, and consistent contributions to cutting-edge research make him an ideal candidate for recognition through prestigious awards like the Best Researcher Award.

🔬 Research Focus:

Dr. Wang Sen’s research centers on tumor microenvironment regulation, angiogenesis, autophagy, and tumor stem cell interactions, with a strong focus on gastrointestinal and renal cancers. His work often integrates cellular signaling, exosome biology, and gene expression regulation to understand cancer progression and metastasis. Key interests include pathways involving INSR/FGF5/ADRB2, ALDOC, and MT1G, which he investigates for their roles in tumor metabolism and vascular dynamics. Dr. Wang combines clinical relevance with basic science, aiming to translate molecular findings into diagnostic tools or therapeutic targets. His innovative studies on betulinic acid, p53-mediated pathways, and epigenetic modifications contribute to the broader field of precision oncology. His interdisciplinary approach—bridging pharmacology, molecular biology, and clinical application—positions him as a dynamic researcher capable of advancing medical science.

📚 Publications Top Notes:

  1. 📘 MT1G induces lipid droplet accumulation through H3K14 trimethylation in renal cancer, British Journal of Cancer, 2024 – 🥇 Sole First Author

  2. 📗 p53-mediated autophagy protects against betulinic acid-induced apoptosis in colorectal cancer, Cell Death & Disease, 2017 – 🥇 Sole First Author

  3. 📕 FOXS1 is regulated by GLI1/miR-125a-5p, promotes proliferation and EMT in gastric cancer, Scientific Reports, 2019 – 🥇 Sole First Author

  4. 📙 Identification of the human HAS3 promoter region, Biochemical and Biophysical Research Communications, 2015 – 🥇 Sole First Author

  5. 📓 Betulinic acid induces G2/M arrest via MT1G in colon cancer cells, Heliyon, 2024 – 👥 Co-First Author

  6. 📔 PCDH17 induces colorectal cancer metastasis by disrupting vascular barriers, Cell Death and Disease, 2025 – 🧬 Contributor

  7. 📒 OX40 activation drives tumor escape via S1P/YAP angiogenesis, Journal of Clinical Investigation, 2025 – 🧬 Contributor

🧾 Conclusion:

Dr. Wang Sen is a highly qualified and worthy candidate for the Best Researcher Award. His impressive portfolio—spanning publications, funded projects, patents, and recognized awards—shows that he is not only producing important knowledge but also moving toward real-world application in cancer therapeutics. With continued focus on global engagement and translational outcomes, he is poised to become a leading figure in molecular oncology. His scientific rigor, innovation, and leadership embody the spirit of this award.

Weifen Zhang | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Prof. Weifen Zhang | Cancer Cell Biology | Best Researcher Award

Prof. Weifen Zhang , Shandong Second Medical University , China

Professor Weifen Zhang is a renowned scientist in pharmaceutical sciences, serving as a Professor at the School of Pharmacy, Shandong Second Medical University. She also directs the Shandong Engineering Research Center for Intelligent Materials and Regenerative Medicine and the Pharmaceutical Experimental Teaching Center. With over 50 SCI-indexed publications and 27 national and international patents, her contributions have significantly influenced the development of targeted drug delivery systems and smart biomaterials. A recipient of the State Council Special Allowance and recognized as a Shandong Provincial Outstanding Expert, Professor Zhang combines academic excellence with practical innovation. She has led and collaborated on numerous national-level research projects, focusing on novel therapeutic strategies for cancer, regenerative medicine, and nano-drug technologies. Additionally, she plays a prominent role in scientific publishing as a guest editor and reviewer for leading journals. Her dedication to interdisciplinary research continues to shape the future of pharmaceutical technology.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. 📚 High Research Productivity: Over 50 SCI-indexed publications in high-impact journals such as ACS Applied Materials & Interfaces, Journal of Biomedical Nanotechnology, and Science China Materials.

  2. 💡 Innovation & Intellectual Property: Holds 27 national and international patents, showing a strong translation of academic work into real-world applications.

  3. 🔬 Research Focus & Impact: Cutting-edge work in targeted drug delivery systems, intelligent biomaterials, and regenerative medicine, especially impactful in oncology.

  4. 🎯 Project Leadership: Principal Investigator for multiple nationally funded projects, managing significant funding amounts and driving original discoveries.

  5. 🌐 Academic Influence: Serves as a guest editor and reviewer for leading scientific journals, contributing to quality control and peer knowledge advancement.

  6. 📖 Educational Impact: Contributions to national-level textbooks like Pharmaceutics and Pharmaceutical English highlight her role in shaping future pharmaceutical education.

  7. 🤝 Industry Collaboration: Active collaborations with companies like NOIMAIER (Shandong) Medical Technology Co., Ltd, demonstrating practical application and outreach.

⚠️ Areas for Improvement:

  1. 🌍 Global Outreach: While her influence is strong nationally, increased participation in international conferences, collaborations, and global visibility would further elevate her stature.

  2. 🎙️ Public Engagement: Enhanced involvement in science communication, including talks, public articles, or media, could broaden her societal impact.

  3. 🌐 Online Presence: A more visible online research profile (e.g., Google Scholar, ResearchGate, LinkedIn) could help in networking and research dissemination globally.

🎓 Education:

Professor Weifen Zhang received comprehensive training in pharmaceutical sciences, culminating in a doctorate in pharmacy or a related biomedical field (specific degree and institution not provided in the current profile). Her academic journey has been deeply rooted in advancing applied pharmaceutical research, especially in the field of drug delivery and intelligent materials. Her educational background laid the foundation for her specialization in nanoformulations, regenerative medicine, and drug resistance reversal. Professor Zhang has supplemented her academic credentials with continued professional development through her work with major national science foundations and governmental innovation programs. Her commitment to combining traditional pharmaceutical training with cutting-edge material science has enabled her to become a leader in translational research. Although the detailed degrees and institutions are not specified, her track record in high-impact research, publications, and academic leadership reflects a strong and diverse educational background.

🧪 Experience:

Professor Zhang brings over two decades of experience in pharmaceutical sciences, nanomedicine, and biomaterial engineering. She has served in multiple leadership roles, including Director of both the Shandong Engineering Research Center for Intelligent Materials and Regenerative Medicine and the Pharmaceutical Experimental Teaching Center at Shandong Second Medical University. As Principal Investigator on numerous high-profile projects funded by the National Natural Science Foundation of China and regional innovation programs, she has demonstrated excellence in both basic and translational research. Her industrial collaborations and consultancy projects, such as those with NOIMAIER Medical Technology, reflect her ability to translate scientific innovation into practical solutions. Her experience is also reflected in her active editorial and peer review contributions to top-tier journals, as well as her involvement in educational contributions through national textbook projects. Her academic, industrial, and clinical translational experiences make her a uniquely qualified and impactful researcher.

🔬 Research Focus:

Professor Weifen Zhang’s research is at the forefront of targeted drug delivery, intelligent biomaterials, and regenerative medicine. Her primary scientific focus involves developing novel nanoparticle-based platforms to improve therapeutic outcomes in diseases such as non-small cell lung cancer. She has led pioneering studies in dual-drug synergistic delivery, utilizing agents like quercetin and paclitaxel, aimed at overcoming drug resistance. Her lab also explores smart, biodegradable materials, such as Bletilla striata polysaccharide microneedles, for innovative therapeutic applications including hair regrowth and skin regeneration. In regenerative medicine, she is advancing bionic materials, such as mineralized collagen scaffolds, for orthopedic and dental use. Additionally, she works on plant-derived compounds, contributing to both pharmaceutical and agricultural solutions. Through interdisciplinary approaches, including nanotechnology, immunology, and pharmacokinetics, Professor Zhang’s work is positioned to influence both academic research and clinical practice. Her vision continues to shape the field of personalized and precision medicine.

📚 Publications Top Notes:

  1. 📌 Bletilla striata polysaccharide-based dissolving microneedle patch integrated with nanoparticles for promoting hair regrowth

  2. 🧱 Composite scaffolds based on egg membrane and eggshell-derived inorganic particles promote soft and hard tissue repair

  3. 💉 Efficient chemo-immunotherapy leveraging minimalist electrostatic complex nanoparticle as “in situ” vaccine integrated tumor ICD and immunoagonist

  4. 🌿 A Chinese drug-compatibility-based approach to purslane hydrogels for acute eczema therapy

  5. 🔬 Dynamic Covalent Bond-Based Nanoassembly of Curcumin to Enhance the Selective Photothermal Therapy for Tumor Treatment

  6. 🧵 Multifunctional Nanofiber Membranes Constructed by Microfluidic Blow-Spinning to Inhibit Scar Formation at Early Intervention Stage

  7. 📄 Corrigendum to “Synergistically enhanced cancer immunotherapy by combining protamine-based nanovaccine with PD-L1 gene silence nanoparticle”

  8. 💉 Minimalist “in situ” tumor vaccine leveraging versatile dendrimer nanoplatform coordinated ICD and immunoagonist for boosted chemoimmunotherapy

  9. 🧬 A minimalist cancer cell membrane-shielded biomimetic nanoparticle for nasopharyngeal carcinoma active-targeting therapy

  10. ⚗️ Biodegradable Manganese-Containing Mesoporous Silica Nanoparticles for Precisely Controlled Quercetin Delivery

 

📌 Conclusion:

Professor Weifen Zhang demonstrates exceptional qualifications for the Best Researcher Award. Her deep scientific contributions, robust patent portfolio, influential publications, and national leadership in pharmaceutical innovation mark her as a leader in biomedical research. With a few enhancements in global visibility and science communication, her already impressive profile could reach even greater heights.

Huifeng Hao | Tumor pharmacology | Best Researcher Award

Posted on by sciencefather

Dr. Huifeng Hao | Tumor pharmacology | Best Researcher Award

Dr. Huifeng Hao , Peking University Cancer Hospital , China

Dr. Huifeng Hao is an Assistant Investigator at Peking University Cancer Hospital, specializing in the integration of Chinese and Western medicine. He holds a Ph.D. from Peking University Health Science Center, where he explored Chinese-Western medical integration. His research journey began with a Bachelor’s in Clinical Medicine from Hebei Medical University. Dr. Hao has accumulated valuable postdoctoral experience at Peking Union Medical College (PUMC) in Vascular Pharmacology. His work has greatly contributed to the understanding of cancer progression, focusing on the interactions between cancer cells and vascular endothelial cells and the therapeutic effects of Traditional Chinese Medicine. With over a decade of expertise, Dr. Hao has published extensively in renowned journals, addressing critical topics in cancer research, endothelial cell function, and vascular health.

Publication Profile:

Orcid

Strengths for the Award:

  1. Extensive Educational and Research Background: Dr. Huifeng Hao has a comprehensive and solid academic foundation. With a Bachelor’s degree in Clinical Medicine from Hebei Medical University and a Ph.D. in the Integration of Chinese and Western Medicine from Peking University Health Science Center, his educational background is robust. Moreover, his postdoctoral research in Vascular Pharmacology at Peking Union Medical College significantly bolsters his expertise, particularly in vascular biology and its implications in cancer progression.

  2. Groundbreaking Research Areas: Dr. Hao’s research primarily focuses on the complex interactions between cancer cells and vascular endothelial cells, along with exploring how Traditional Chinese Medicine (TCM) can influence cancer progression. This intersection of modern pharmacology and traditional medicine offers a unique and innovative approach to cancer therapy. His studies on cancer metastasis, endothelial cell signaling, and the use of TCM as a potential therapeutic strategy for cancer represent cutting-edge work.

  3. Impressive Publication Record: Dr. Hao has co-authored numerous high-impact publications in leading journals, such as Phytomedicine, Frontiers in Pharmacology, Journal of Ethnopharmacology, and Journal of Cellular and Molecular Medicine. His work spans across critical cancer pathways, pharmacological interventions, and the exploration of novel therapeutic agents like Marsdenia Tenacissima and Berberine in combating metastasis and endothelial dysfunction.

    • His 2022 papers on the modified Bu-Fei decoction’s effects on lung metastasis and the role of CUEDC2 in promoting breast cancer progression are particularly notable for their novel findings and potential clinical applications.

  4. Collaborative and Multi-Disciplinary Research: Dr. Hao’s ability to collaborate with a wide array of experts and researchers in diverse fields demonstrates his interdisciplinary approach to solving complex scientific questions. This collaboration enhances the relevance and applicability of his work in various research areas, particularly in cancer biology, pharmacology, and integrative medicine.

  5. Pioneering Work on TCM in Cancer Therapy: Dr. Hao’s research on the role of Traditional Chinese Medicine (TCM) in cancer therapy is especially noteworthy. His studies examining how TCM influences tumor microenvironments and endothelial cell interactions provide critical insights into how integrative medicine might be leveraged to treat cancer in combination with conventional therapies. This pioneering research has the potential to redefine cancer treatments and offer patients holistic therapeutic options.

  6. Strong Impact on Cancer Research: His work on vascular pharmacology, tumor angiogenesis, and metastasis in lung cancer, particularly through the modulation of transforming growth factor beta receptors and nitric oxide signaling, has significant implications for the development of new cancer therapies. His publications are contributing valuable knowledge toward better understanding cancer progression and discovering more effective treatments.

Areas for Improvement:

  1. Broader Research Scope in Clinical Settings: While Dr. Hao’s research has focused heavily on preclinical studies, including animal models and cellular assays, expanding his research into clinical trials or human-based studies would provide essential validation for his findings. Involving clinical datasets and patient-centered research could strengthen the real-world applicability of his work.

  2. Increase in Independent Research Funding: While Dr. Hao has contributed significantly to various collaborative projects, securing independent research grants would allow him more freedom to explore his unique research hypotheses in greater depth and broaden the scope of his investigations.

  3. Expansion of International Collaborations: While Dr. Hao’s collaborations are impressive, further expanding his international network could provide additional insights and allow him to take his research to the global forefront. Partnerships with leading international cancer research institutions could also amplify the impact of his work.

Education:

  • 2004.09-2009.06: Hebei Medical University (Bachelor Degree in Clinical Medicine)
  • 2009.09-2014.06: Peking University Health Science Center (Ph.D. in Integration of Chinese and Western Medicine)
  • 2014.09-2018.08: Peking Union Medical College (Postdoctoral Training in Vascular Pharmacology)

Dr. Hao’s academic journey spans over a decade of rigorous training, blending Western scientific research with Traditional Chinese Medicine. He received his bachelor’s degree in clinical medicine and later pursued his Ph.D. in an interdisciplinary program that focused on integrating these two approaches to medicine. His postdoctoral research in vascular pharmacology furthered his expertise in understanding the physiological and molecular mechanisms of cancer-related vascular changes.

Experience:

  • 2014.09-2018.08: Postdoctoral Researcher, Peking Union Medical College, Vascular Pharmacology
  • 2018.08-Present: Assistant Investigator, Peking University Cancer Hospital, Integration of Chinese and Western Medicine

Dr. Hao’s research career spans significant academic institutions in China. During his postdoctoral research at PUMC, he specialized in vascular pharmacology, focusing on the molecular pathways involved in tumor vasculature. At Peking University Cancer Hospital, Dr. Hao continues to investigate how traditional medicine can alter the interactions between cancer cells and endothelial cells, with a goal of developing novel therapeutic strategies for cancer treatment. His interdisciplinary approach has led to multiple breakthrough discoveries in cancer biology and integrative medicine.

Research Focus:

Dr. Hao’s primary research areas include:

  • Investigating the interactions between cancer cells and vascular endothelial cells, and how these affect cancer progression
  • Exploring the role of Traditional Chinese Medicine (TCM) in regulating cancer cell interactions within the tumor microenvironment, especially with endothelial cells

By bridging the gap between modern biomedical science and traditional medicine, Dr. Hao aims to develop therapies that utilize both modalities to inhibit tumor growth and metastasis. His work focuses on understanding how TCM can modulate endothelial cells and vascular pathways, potentially leading to new treatments for cancer that are more holistic and effective.

Publications Top Notes:

  1. Modified Bu-Fei decoction inhibits lung metastasis via suppressing angiopoietin-like 4 🫁🦠
  2. CUEDC2 Drives β-Catenin Nuclear Translocation and Promotes Triple-Negative Breast Cancer Tumorigenesis 🧬💥
  3. Berberine Suppresses Lung Metastasis of Cancer via Inhibiting Endothelial Transforming Growth Factor Beta Receptor 1 🌱🏥
  4. Marsdenia tenacissima extract disturbs the interaction between tumor-associated macrophages and non-small cell lung cancer cells by targeting HDGF 🌿🧫
  5. The cyclic adenosine monophosphate elevating medicine, forskolin, reduces neointimal formation and atherogenesis in mice 🐭💉
  6. Nitric oxide, a communicator between tumor cells and endothelial cells, mediates the anti-tumor effects of Marsdenia Tenacissima Extract (MTE) 💡🔬
  7. Marsdenia tenacissima extract promotes gefitinib accumulation in tumor tissues of lung cancer xenograft mice via inhibiting ABCG2 activity 💊🔬
  8. Marsdenia tenacissima extract dilated small mesenteric arteries via stimulating endothelial nitric oxide synthase and inhibiting calcium influx 🧪🩸
  9. Protective Role of mPGES-1 (Microsomal Prostaglandin E Synthase-1)-Derived PGE(2) (Prostaglandin E-2) and the Endothelial EP4 (Prostaglandin E Receptor) in Vascular Responses to Injury 💥🩺
  10. Loss of Endothelial CXCR7 Impairs Vascular Homeostasis, and Cardiac Remodeling After Myocardial Infarction ❤️🫀

Conclusion:

Dr. Huifeng Hao’s contributions to cancer research, particularly the intersection of TCM and Western medicine, make him an excellent candidate for the Best Researcher Award. His innovative studies, combined with his dedication to advancing cancer treatment, position him as a leading researcher in his field. His continued research promises to significantly impact both scientific understanding and clinical practices in cancer therapy.

Annoor Awadasseid | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Dr. Annoor Awadasseid | Cancer Cell Biology | Best Researcher Award

Dr. Annoor Awadasseid , Zhejiang University of Technology , Sudan

Dr. Annoor Awadasseid is a dedicated biochemist and molecular biologist specializing in medicinal chemistry, with a profound focus on cancer treatment. With a rich background in the exploration of novel small-molecule compounds, his research is at the forefront of developing potential therapeutic drugs for oncology. Dr. Awadasseid has made significant contributions to biochemistry, molecular biology, and cancer therapy, integrating his expertise to evaluate promising compounds. Passionate about enhancing patient outcomes, he collaborates extensively with interdisciplinary teams and mentors junior researchers. Currently, he is a Senior Researcher at Hangzhou Qingzhenghong Technology Co., Ltd., where he leads oncology-focused R&D initiatives, developing novel cancer therapies. He has authored numerous high-impact publications, showcasing his commitment to advancing therapeutic approaches for cancer care.

Publication Profile:

Google Scholar

Strengths for the Award:

Dr. Annoor Awadasseid exhibits outstanding qualities as a researcher in the field of biochemistry and molecular biology, particularly within cancer therapeutics. His expertise in evaluating small-molecule compounds for cancer treatment is evident through his advanced knowledge of biochemical processes, medicinal chemistry, and molecular biology techniques. Dr. Awadasseid has significantly contributed to the design and development of novel therapeutic agents, particularly targeting the PD-1/PD-L1 immune checkpoint pathway, which is critical for cancer immunotherapy. His ability to collaborate with interdisciplinary teams and mentor junior researchers demonstrates a strong leadership role in advancing scientific knowledge and fostering innovation. His extensive publication record in prestigious journals, alongside the recognition he has received via multiple scholarships and awards, further attests to the high impact of his research and contributions to improving patient care.

Areas for Improvement:

While Dr. Awadasseid’s research is impressive and impactful, further diversification of research methodologies could enhance his work. For instance, incorporating more cutting-edge computational techniques and expanding collaborations with clinical research teams could accelerate the translation of his lab-based discoveries into clinical applications. Additionally, increasing visibility in international scientific conferences would allow Dr. Awadasseid to expand his professional network, share insights, and potentially collaborate on global-scale projects. Engaging in multidisciplinary research that spans beyond oncology could also create new avenues for discovery and broaden his research impact.

Education:

Dr. Awadasseid’s academic journey includes a Ph.D. in Medicinal Chemistry from the University of Chinese Academy of Sciences (2017-2020), where he specialized in the design and evaluation of therapeutic compounds. Prior to that, he earned another Ph.D. in Biochemistry and Molecular Biology from Dalian Medical University (2014-2017). His earlier studies culminated in a Master’s degree in Biochemistry and Molecular Biology from Northeast Normal University (2012-2014). These rigorous educational experiences have honed his skills in biochemical and molecular techniques, which form the foundation for his groundbreaking research in cancer therapy. Dr. Awadasseid’s extensive training across multiple renowned institutions equipped him with the tools to explore novel therapeutic pathways, ultimately paving the way for his contributions to drug discovery and cancer treatment.

Experience:

Dr. Awadasseid has over a decade of experience in biochemistry, molecular biology, and medicinal chemistry. Following his postdoctoral fellowship at Zhejiang University of Technology (2020-2024), where he focused on small-molecule drug evaluation for cancer therapy, he became a Senior Researcher at Hangzhou Qingzhenghong Technology Co., Ltd. (2024-present). In this role, he leads R&D initiatives, specializing in the discovery and development of novel small-molecule compounds for oncology. His work includes evaluating drug efficacy through preclinical models, optimizing therapeutic candidates, and integrating interdisciplinary insights to drive advancements in targeted cancer therapies. Dr. Awadasseid’s expertise spans a variety of techniques, including CRISPR/Cas9 gene editing, flow cytometry, and qPCR, supporting his pivotal contributions to improving cancer treatment and patient outcomes. He also mentors junior researchers and contributes to intellectual property creation, including patents and publications in prestigious journals.

Awards and Honors:

Dr. Awadasseid has received prestigious accolades throughout his career. He was awarded the CAS-TWAS President’s Fellowship Programme (2017-2020) for his Ph.D. studies at the University of Chinese Academy of Sciences, recognizing his potential for significant scientific contributions. Additionally, he received the Liaoning Provincial Government Scholarship (2014-2017) while pursuing his Ph.D. at Dalian Medical University. The Chinese Government Scholarship (2012-2014) was awarded to him for his Master’s degree studies at Northeast Normal University, reflecting his academic excellence and commitment to advancing research in biochemistry and molecular biology. These scholarships and awards highlight Dr. Awadasseid’s dedication to his field, his research accomplishments, and his potential to make lasting impacts in the realm of cancer therapy and medicinal chemistry.

Research Focus:

Dr. Awadasseid’s research is centered on the development and evaluation of novel small-molecule compounds for cancer treatment, specifically focusing on their mechanisms and potential as therapeutic agents. His work aims to identify promising candidates that could enhance patient outcomes in oncology. He has a strong interest in the design and synthesis of therapeutic molecules, particularly those targeting the PD-1/PD-L1 pathway and other key molecules involved in cancer progression. Through extensive preclinical testing, Dr. Awadasseid evaluates the efficacy of these compounds, with a particular emphasis on their ability to target specific cancer pathways, including apoptosis, immune response modulation, and signal transduction. His research employs a wide range of molecular and biochemical techniques, including CRISPR/Cas9 gene editing, qPCR, flow cytometry, and various microscopy methods, to assess the therapeutic potential of novel compounds. Ultimately, Dr. Awadasseid aims to contribute to the development of more effective, targeted therapies for cancer patients.

Publication Top Notes:

  1. Design, synthesis and biological evaluation of novel TMPRSS2-PROTACs with florosubstituted 4-guanidino-N-phenylbenzamide derivative ligands. 🔬💊
  2. Design, synthesis, and evaluation of antitumor activity of 2-arylmethoxy-4-(2-fluoromethyl-biphenyl-3-ylmethoxy) benzylamine derivatives as PD-1/PD-L1 inhibitors. 🧬💥
  3. Small molecule and PROTAC molecule experiments in vitro and in vivo, focusing on mouse PD-L1 and human PD-L1 differences as targets. 🔬🐭
  4. Recent advances and mechanisms of action of PD-L1 degraders as potential therapeutic agents. 💡📚
  5. Design, synthesis, anti-tumor activity and mechanism of novel PROTACs as degraders of PD-L1 and inhibitors of PD-1/PD-L1 interaction. 🔧🎯
  6. Current studies and future promises of PD-1 signal inhibitors in cervical cancer therapy. 🎗️🔬
  7. A Review on the Anticancer Activity of Carbazole-based Tricyclic Compounds. 📖🔍
  8. Design, Synthesis, and Antitumor Activity Evaluation of 2-Arylmethoxy-4-(2, 2′-dihalogen-substituted biphenyl-3-ylmethoxy) Benzylamine Derivatives as Potent PD-1/PD-L1 Inhibitors. 🧪🧫
  9. PD-L1 dimerisation induced by biphenyl derivatives mediates anti-breast cancer activity via the non-immune PD-L1–AKT–mTOR/Bcl2 pathway. 🧬💥
  10. Design, synthesis and bioactivity of novel naphthalimide-benzotriazole conjugates against A549 cells via targeting BCL2 G-quadruplex and inducing autophagy. 🧪⚡

Conclusion:

Dr. Awadasseid is undoubtedly a strong candidate for the Best Researcher Award due to his exceptional contributions to the field of cancer research. His innovative approach to discovering therapeutic small-molecule compounds, coupled with his ability to collaborate across disciplines, positions him as a leader in the biochemistry and molecular biology community. By continuing to refine his research techniques and expanding his collaborations, Dr. Awadasseid is likely to further enhance the scope and impact of his work. His ultimate goal of improving patient care and treatment modalities places him in alignment with the mission of the Best Researcher Award, making him a fitting candidate for this prestigious recognition.